



iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer

August 5, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies.

"As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we're excited to welcome Dr. Feltquate as Chief Medical Officer," said Michel Dethoux, Ph.D., president and chief executive officer of iTeos. "His leadership experience, track record in immuno-oncology drug development, and insights into biomarker development will prove invaluable as we continue to advance our pipeline. We look forward to the integral role he will play in shaping our clinical development strategy and in strengthening our organization as we continue in a defining year for the company."

Dr. Feltquate brings to iTeos nearly 20 years of immuno-oncology clinical development, translational medicine, and diagnostic assay advancement experience. Prior to joining iTeos, he was Chief Medical Officer at Palleon Pharmaceuticals where he oversaw the clinical strategy and development of its glyco-immunology therapeutics pipeline. Before that, Dr. Feltquate was the Global Head of Hematology Development and Chair of the Precision Medicine Leadership Team at Novartis. Previously, he held numerous leadership positions at Bristol Myers Squibb including Head of Oncology Early Clinical Development and Development Leader for Ipilimumab / Nivolumab Life Cycle Management. As the Nivolumab Clinical Head, Dr. Feltquate was responsible for the clinical development of the first PD-1 inhibitor from proof of concept through initial registrations in non-small cell lung cancer, melanoma, and renal cell carcinoma. Dr. Feltquate earned a B.S. in Biology from the Massachusetts Institute of Technology and an M.D./Ph.D. in Immunology from the University of Massachusetts Medical School. He completed internal medicine training at Dartmouth Hitchcock Medical Center and medical oncology training at Memorial Sloan Kettering Cancer Center.

"I am delighted to join iTeos at a time when the company is accelerating its TIGIT franchise and strategically focused on building a rich pipeline of new targets for patients in need," said Dr. Feltquate. "Being part of a company that is at the forefront of developing an innovative oncology pipeline, ingrained in a scientifically disciplined, data driven approach, represents an incredible opportunity to bring novel and potentially transformative therapies to patients."

About iTeos Therapeutics, Inc.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company's innovative pipeline includes three clinical-stage programs targeting novel, validated immunosuppressive pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

About Belrestotug (EOS-448/ GSK4428859A)

Belrestotug is an Fc active human immunoglobulin G1, or IgG1, monoclonal antibody (mAb) targeting T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT), an important inhibitory receptor which contributes to the suppression of innate and adaptive immune responses against cancer. As an optimized high-affinity, potent anti-TIGIT mAb, belrestotug is designed to enhance the antitumor response through a multifaceted immune modulatory mechanism by engaging with TIGIT and FcγR, a key regulator of immune responses which induces cytokine release and antibody dependent cellular cytotoxicity (ADCC). The therapeutic candidate is progressing in multiple indications in collaboration with GSK.

Internet Posting of Information

iTeos routinely posts information that may be important to investors in the 'Investors' section of its website at www.iteostherapeutics.com. The Company encourages investors and potential investors to consult our website regularly for important information about iTeos.

Forward-Looking Statements

This press release contains forward-looking statements. Any statements that are not solely statements of historical fact are forward-looking statements. Words such as "believe," "anticipate," "plan," "expect," "will," "may," "intend," "prepare," "look," "potential," "possible" and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements relating to the potential benefits of David Feltquate's appointment as the Company's Chief Medical Officer and the potential to bring novel and transformative therapies to patients.

These forward-looking statements involve risks and uncertainties, many of which are beyond iTeos' control. Actual results could materially differ from those stated or implied by these forward-looking statements as a result of such risks and uncertainties. Known risk factors include the following: the data for our product candidates may not be sufficient for obtaining regulatory approval to move into later stage trials or to commercialize products; iTeos may not be able to execute on its business plans, including meeting its expected or planned regulatory milestones and timelines, research and clinical development plans, and bringing its product candidates to market, for various reasons, some of which may be outside of iTeos' control, including possible limitations of company financial and other resources, manufacturing limitations that may not be anticipated or resolved for in a timely manner, negative developments in the field of immuno-oncology, and regulatory, court or agency decisions; and those risks identified under the heading "Risk Factors" in iTeos' Quarterly Report on Form 10-Q for the period ended March 31, 2024 filed with the Securities and Exchange Commission (SEC) as well as other SEC filings made by the Company which you are encouraged to review.

Any of the foregoing risks could materially and adversely affect iTeos' business, results of operations and the trading price of iTeos' common stock. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. iTeos does not undertake any

obligation to publicly update its forward-looking statements other than as required by law.

For further information, please contact:

Investor Contact:

Carl Mauch

iTeos Therapeutics, Inc.

carl.mauch@iteosterapeutics.com

Media Contact:

media@iteosterapeutics.com